Treatment For Metastatic Hormone Sensitive Prostate Cancer (M - HSPC)

Co-Host: Kelvin Moses, MD At the conclusion of these activities, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of metastatic HSPC. 2. Describe the risks and benefits of treatment for metastatic HSPC. CME Available: auau.auanet.org/node/26063 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma